ZA200202760B - Substituted pyridines and pyridazines with angiogenesis inhibiting activity. - Google Patents

Substituted pyridines and pyridazines with angiogenesis inhibiting activity.

Info

Publication number
ZA200202760B
ZA200202760B ZA200202760A ZA200202760A ZA200202760B ZA 200202760 B ZA200202760 B ZA 200202760B ZA 200202760 A ZA200202760 A ZA 200202760A ZA 200202760 A ZA200202760 A ZA 200202760A ZA 200202760 B ZA200202760 B ZA 200202760B
Authority
ZA
South Africa
Prior art keywords
pyridazines
inhibiting activity
substituted pyridines
angiogenesis inhibiting
angiogenesis
Prior art date
Application number
ZA200202760A
Other languages
English (en)
Inventor
Jacques P Dumas
Stephen J Boyer
Julie A Dixon
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA200202760B publication Critical patent/ZA200202760B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ZA200202760A 1999-09-28 2002-04-09 Substituted pyridines and pyridazines with angiogenesis inhibiting activity. ZA200202760B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
ZA200202760B true ZA200202760B (en) 2003-10-29

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202760A ZA200202760B (en) 1999-09-28 2002-04-09 Substituted pyridines and pyridazines with angiogenesis inhibiting activity.

Country Status (35)

Country Link
EP (1) EP1228063B1 (cs)
JP (1) JP4919567B2 (cs)
KR (3) KR100895572B1 (cs)
CN (3) CN100422173C (cs)
AR (3) AR025752A1 (cs)
AT (1) ATE422494T1 (cs)
AU (1) AU782820B2 (cs)
BG (1) BG65860B1 (cs)
BR (1) BRPI0014382B8 (cs)
CA (1) CA2385817C (cs)
CO (1) CO5200835A1 (cs)
CZ (1) CZ304767B6 (cs)
DE (1) DE60041548D1 (cs)
DO (1) DOP2000000070A (cs)
EE (1) EE05258B1 (cs)
ES (1) ES2320525T3 (cs)
GT (1) GT200000158A (cs)
HR (1) HRP20020308A2 (cs)
HU (1) HU230223B1 (cs)
IL (3) IL148880A0 (cs)
MA (1) MA25563A1 (cs)
MX (1) MXPA02003156A (cs)
MY (3) MY143377A (cs)
NO (1) NO20021520L (cs)
NZ (1) NZ518589A (cs)
PA (1) PA8503201A1 (cs)
PE (1) PE20010607A1 (cs)
PL (1) PL205957B1 (cs)
RS (1) RS50369B (cs)
RU (1) RU2260008C2 (cs)
SK (1) SK287417B6 (cs)
TW (1) TW593315B (cs)
UA (1) UA75053C2 (cs)
WO (1) WO2001023375A2 (cs)
ZA (1) ZA200202760B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7993801A (en) * 2000-08-09 2002-02-18 Astrazeneca Ab Chemical compounds
DE60126997T2 (de) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
HRP20050788A2 (en) * 2003-03-11 2006-12-31 Novartis Ag Use of isoquinoline derivatives for treating cancer and map kinase related diseases
WO2004089412A1 (ja) * 2003-04-08 2004-10-21 Mitsubishi Pharma Corporation 特異的ｎａｄ(ｐ)ｈオキシダーゼ抑制剤
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007118602A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
JP2020519576A (ja) 2017-05-16 2020-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療
JP7624404B2 (ja) * 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
AU705229B2 (en) * 1994-08-09 1999-05-20 Eisai R&D Management Co., Ltd. Fused pyridazine compound
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
BR9912938B1 (pt) * 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
US6706731B2 (en) * 2000-02-09 2004-03-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase

Also Published As

Publication number Publication date
TW593315B (en) 2004-06-21
YU22902A (sh) 2004-12-31
BR0014382B1 (pt) 2014-04-01
NO20021520L (no) 2002-05-23
DOP2000000070A (es) 2002-02-28
MA25563A1 (fr) 2002-10-01
AR082231A2 (es) 2012-11-21
BG65860B1 (bg) 2010-03-31
BG106637A (bg) 2003-02-28
MY143377A (en) 2011-05-13
MY135058A (en) 2008-01-31
BRPI0014382B8 (pt) 2021-05-25
ATE422494T1 (de) 2009-02-15
WO2001023375A2 (en) 2001-04-05
KR100890473B1 (ko) 2009-03-26
HUP0202704A2 (hu) 2002-12-28
IL193368A (en) 2011-05-31
HUP0202704A3 (en) 2003-12-29
IL193367A0 (en) 2009-02-11
BR0014382A (pt) 2003-06-24
AU782820B2 (en) 2005-09-01
AU1569601A (en) 2001-04-30
IL148880A0 (en) 2002-09-12
SK287417B6 (sk) 2010-09-07
CA2385817A1 (en) 2001-04-05
CA2385817C (en) 2010-05-04
HU230223B1 (en) 2015-10-28
RU2260008C2 (ru) 2005-09-10
PE20010607A1 (es) 2001-07-12
PA8503201A1 (es) 2002-08-26
CO5200835A1 (es) 2002-09-27
IL193367A (en) 2011-03-31
MXPA02003156A (es) 2002-09-30
EE05258B1 (et) 2010-02-15
HRP20020308A2 (en) 2004-06-30
KR20080086547A (ko) 2008-09-25
CN1420879A (zh) 2003-05-28
CZ20021444A3 (cs) 2002-08-14
PL366342A1 (en) 2005-01-24
HK1091818A1 (zh) 2007-01-26
HRP20020308B1 (cs) 2013-01-31
GT200000158A (es) 2002-03-16
EP1228063B1 (en) 2009-02-11
CZ304767B6 (cs) 2014-10-08
KR20080091505A (ko) 2008-10-13
AR082232A2 (es) 2012-11-21
RS50369B (sr) 2009-11-10
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
KR100895571B1 (ko) 2009-04-29
ES2320525T3 (es) 2009-05-25
HK1091819A1 (zh) 2007-01-26
KR100895572B1 (ko) 2009-04-29
NZ518589A (en) 2005-03-24
JP4919567B2 (ja) 2012-04-18
PL205957B1 (pl) 2010-06-30
WO2001023375A3 (en) 2002-05-02
CN100374435C (zh) 2008-03-12
DE60041548D1 (de) 2009-03-26
CN100422172C (zh) 2008-10-01
UA75053C2 (en) 2006-03-15
MY143580A (en) 2011-05-31
AR025752A1 (es) 2002-12-11
IL193368A0 (en) 2009-02-11
JP2003526632A (ja) 2003-09-09
SK5912002A3 (en) 2003-01-09
EE200200161A (et) 2003-08-15
CN100422173C (zh) 2008-10-01
KR20020038775A (ko) 2002-05-23
CN1769283A (zh) 2006-05-10
NO20021520D0 (no) 2002-03-26

Similar Documents

Publication Publication Date Title
ZA200202760B (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity.
HUP0001046A3 (en) Phthalazines with angiogenesis inhibiting activity
HRP20030306A2 (en) Pyridine derivatives with ikb-kinase (ikk-?) inhibiting activity
ZA982853B (en) Nicotinamide derivatives.
ZA200109847B (en) 3α-hydroxy-3B methoxymethyl-21-heterocycle substituted steroids with anesthetic activity.
MXPA01011312A (es) Silla para bebe.
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
ZA200202542B (en) Treating sleep disorders using desloratadine.
HUP0301230A3 (en) Phenylpyridazine derivatives and drugs containing the same
IL147885A0 (en) Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
IL143772A0 (en) Synergistic tumorcidal response induced by histamine
GB9904301D0 (en) Furniture arrangement
GB9903439D0 (en) Activity bib
ZA200006189B (en) Furniture.
HUP0202197A3 (en) Borrelidine derivatives inhibiting angiogenesis, and medicaments containing the same
ZA200004964B (en) Geysers.
ZA992468B (en) An item of furniture.
TW568029U (en) Improved furniture caster structure
GB0006298D0 (en) Microbial residued and filterate tobacco
IT1311964B1 (it) Struttura componibile per arredi domestici ed elementi divisori.
ZA200001645B (en) Stoker mat.
ZA200003586B (en) Therapeutic article.
ZA992203B (en) Furniture.
ZA200109012B (en) Androgen glycosides and androgenic activity thereof.